Dr. Melisko on the MA.17R Study for ER+ Breast Cancer

Michelle E. Melisko, MD
Published: Thursday, Nov 09, 2017



Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

The MA.17R study was a follow-up of the trial MA.17 where patients received 5 years of tamoxifen and were then randomized to receive placebo or an aromatase inhibitor (AI). More than 10 years ago, it was discovered that continuing an AI was beneficial, states Melisko.

MA.17R looked at the extension of an AI beyond 5 years, evaluating the added benefit of continuing an AI for 10 years compared to 5 years. Some women in the study received hormonal therapy for 15 years.

This trial met a statistically significant endpoint of reducing recurrences and improving disease-free survival. According to Melisko, this data was practice changing.
 


Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

The MA.17R study was a follow-up of the trial MA.17 where patients received 5 years of tamoxifen and were then randomized to receive placebo or an aromatase inhibitor (AI). More than 10 years ago, it was discovered that continuing an AI was beneficial, states Melisko.

MA.17R looked at the extension of an AI beyond 5 years, evaluating the added benefit of continuing an AI for 10 years compared to 5 years. Some women in the study received hormonal therapy for 15 years.

This trial met a statistically significant endpoint of reducing recurrences and improving disease-free survival. According to Melisko, this data was practice changing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x